The CD47 inhibitors market is anticipated to experience substantial growth in the near future, driven by the anticipated launch of late-stage pipeline drugs like evorpacept, the growing number of CD47 inhibitors undergoing clinical trials, and the rising collaborations among companies for the development of CD47 inhibitor drugs. LAS VEGAS , Oct. 8, 2024 /PRNewswire/ -- DelveInsight's CD47 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CD47 inhibitors, market share of individual therapies, and current and forecasted CD47 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ].
Key Takeaways from the CD47 Inhibitors Market Report As per DelveInsight's analysis, the total market size of CD47 inhibitors in the 7MM is expected to surge significantly by 2034. Leading CD47 inhibitor companies such as ALX Oncology, Phanes Therapeutics, Pfizer, Akeso Biopharma, ImmuneOnco Biopharma, and others are developing novel CD47 inhibitors that can be available in the CD47 inhibitors market in the coming years. Some of the key CD47 inhibitors in the pipeline include Evorpacept + Herceptin + Cyramza + Paclitaxel, Evorpacept + Pembrolizumab, PT217, maplirpacept (TTI-622), ligufalimab (AK117), IMM01 , and others.
In June 2024 , SL-172154 received FDA Orphan Drug Designation in Acute Myeloid Leukemia. SL-172154 is an investi.